Marker Therapeutics, Inc. financial data

Symbol
MRKR on Nasdaq
Industry
Pharmaceutical Preparations
Location
4551 Kennedy Commerce Dr., Houston, Texas
State of incorporation
Delaware
Fiscal year end
December 31
Former names
TAPIMMUNE INC. (to 10/17/2018), TAPIMMUNE INC (to 6/29/2017), GENEMAX CORP (to 6/28/2007), EDUVERSE COM (to 6/17/2002)
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 656 % +212%
Debt-to-equity 18 % -77.8%
Return On Equity -36.8 % +68.3%
Return On Assets -31.2 % +51.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.9M shares +1.18%
Common Stock, Shares, Outstanding 8.9M shares +1.14%
Entity Public Float 23.1M USD +1.32%
Common Stock, Value, Issued 8.91K USD +1.26%
Weighted Average Number of Shares Outstanding, Basic 8.9M shares +2.08%
Weighted Average Number of Shares Outstanding, Diluted 8.9M shares +2.08%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 9.62M USD +15.6%
General and Administrative Expense 6.53M USD -33.2%
Operating Income (Loss) -12.8M USD +10.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -14M USD +29%
Income Tax Expense (Benefit) 3.68K USD
Net Income (Loss) Attributable to Parent -5.66M USD +77.3%
Earnings Per Share, Basic -0.64 USD/shares +78.4%
Earnings Per Share, Diluted -0.64 USD/shares +78.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 11.3M USD +76.9%
Assets, Current 14.1M USD +29.1%
Property, Plant and Equipment, Net 11.7M USD -18.5%
Operating Lease, Right-of-Use Asset 5.33M USD -44.4%
Assets 14.1M USD -49.6%
Accounts Payable, Current 1.2M USD -58%
Employee-related Liabilities, Current 57K USD -87.4%
Liabilities, Current 2.3M USD -55.7%
Operating Lease, Liability, Noncurrent 6.82M USD -38.2%
Liabilities 2.3M USD -80.8%
Retained Earnings (Accumulated Deficit) -439M USD -1.31%
Stockholders' Equity Attributable to Parent 11.8M USD -25.9%
Liabilities and Equity 14.1M USD -49.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.84M USD +34.8%
Net Cash Provided by (Used in) Financing Activities 49.1K USD -92.1%
Net Cash Provided by (Used in) Investing Activities 18.7M USD
Common Stock, Shares Authorized 30M shares 0%
Common Stock, Shares, Issued 8.9M shares +1.14%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 11.8M USD -72.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 11.3M USD +76.9%
Deferred Tax Assets, Valuation Allowance 39.7M USD -3.77%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 39.7M USD -3.77%
Operating Lease, Liability 7.49M USD -36.1%
Depreciation 800K USD -63.6%
Lessee, Operating Lease, Liability, to be Paid 9.23M USD -38.4%
Property, Plant and Equipment, Gross 17.8M USD +30.9%
Operating Lease, Liability, Current 665K USD -2.76%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.29M USD -16.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.25M USD +30.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.74M USD -46.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.18M USD -35.5%
Deferred Tax Assets, Operating Loss Carryforwards 29.4M USD -2.39%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.16M USD -37.9%
Operating Lease, Payments 232K USD -26.6%
Additional Paid in Capital 450M USD +0.34%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 4K USD
Current Federal Tax Expense (Benefit) 0 USD
Depreciation, Depletion and Amortization 818K USD +42%
Deferred Tax Assets, Net of Valuation Allowance 1.46M USD -32.8%
Share-based Payment Arrangement, Expense 1M USD -77.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%